To ensure medication safety, Avapritinib has clear contraindications or requires extreme caution when used in specific populations. The following three situations require special attention.

1、 Severe liver dysfunction patients

1. Prohibited use

Patients with severe liver injury are prohibited from using Avapritinib as impaired drug metabolism significantly increases the risk of toxicity.

2. Mild to moderate abnormalities

Such patients may need to start with a lower starting dose and closely monitor liver function indicators after evaluation by a doctor.

2、 Severe renal insufficiency patients

1. Lack of security data

Patients with severe renal insufficiency or end-stage renal disease are generally not recommended to use it as drug excretion may be obstructed.

2. Mild to moderate abnormalities

Such patients need to be carefully evaluated by doctors, taking into account both benefits and risks before making a decision.

3、 Pregnant and lactating women

1. Pregnancy period

Animal experiments have shown embryotoxicity, and pregnant women should avoid using it. Women of childbearing age must use effective contraceptive measures during treatment and for a certain period after discontinuing medication.

2. Breastfeeding period

It is not yet clear whether it is excreted through human milk. To avoid infant exposure, it is recommended to suspend breastfeeding during treatment.

4、 Other groups to be aware of

1. Children

The safety and effectiveness have not been established yet, and it is not recommended to use it.

2. Elderly patients

No need to adjust the dosage separately based on age, but closer monitoring of adverse reactions is required.

Important reminder:

Before starting treatment, it is necessary to inform the doctor of past or current history of liver and kidney diseases, pregnancy plans, or breastfeeding status.

All medication decisions for the above-mentioned population should be individualized by specialized doctors, and do not self medicate or adjust the plan.